Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Stock Short Interest Climbs 74.6%

Fidelity Disruptive Medicine ETF (NASDAQ:FMED) was the recipient of a large growth in short interest in September. As of September 30th, there was short interest totaling 7,209 shares, a growth of 74.6% from the September 15th total of 4,130 shares. Approximately 0.5% of the shares of the company are sold short. Based on an average trading volume of 7,501 shares, the short-interest ratio is currently 1.0 days.

Fidelity Disruptive Medicine ETF Stock Up 1.7%

FMED stock traded up $0.52 during trading on Thursday, reaching $31.16. 2,525 shares of the company’s stock were exchanged, compared to its average volume of 10,407. Fidelity Disruptive Medicine ETF has a 1-year low of $23.48 and a 1-year high of $32.99. The company’s fifty day moving average price is $31.47 and its 200-day moving average price is $28.12. The firm has a market cap of $49.85 million, a PE ratio of 41.33 and a beta of 0.76.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Fidelity Disruptive Medicine ETF stock. Citadel Advisors LLC acquired a new stake in shares of Fidelity Disruptive Medicine ETF (NASDAQ:FMED) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 9,896 shares of the company’s stock, valued at approximately $282,000. Citadel Advisors LLC owned approximately 0.62% of Fidelity Disruptive Medicine ETF as of its most recent SEC filing.

About Fidelity Disruptive Medicine ETF

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.